Court grants preliminary approval of class action settlement on behalf of consumers who purchased Budeprion XL, 300mg or Bupropion Hyrdochloride XL, 150mg. As a result of the Settlement, Defendants who manufacture and distribute the drug, have agreed to injunctive relief consistent with federal regulations to ensure that the key practices complained of in this litigation permanently cease, providing a substantial benefit to the purchasing public. The measures include removing allegedly misleading labeling information, further disclosure of the drug’s testing procedures, monitoring the investigation of consumer complaints, improving quality control and publishing information on future voluntary recalls. Kanner & Whiteley, LLC has been appointed to represent the class. MDL No. 2107 E.D. Pa. 2:09-cv-2811.
For additional information: budeprionxlsettlement.com